RecruitingPhase 1NCT07172971
Neuromuscular
Duchenne Muscular Dystrophy
Also known as DMD, Duchenne MD, dystrophin deficiency
Duchenne muscular dystrophy is caused by mutations in the DMD gene that prevent production of functional dystrophin, a protein essential for muscle membrane stability. Progressive muscle degeneration leads to loss of ambulation typically by
ORPHA:98896 ↗Gene DMD (dystrophin)Prevalence 1-9 per 100,000 (Orphanet)Onset ChildhoodGenetic (X-linked recessive)
61
studies recruiting now
as of 7 Sept 2026
497
studies registered in total
as of 7 Sept 2026
11
countries with a recruiting site
as of 7 Sept 2026
17 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT07587242
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
RecruitingNCT07092540
The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy
RecruitingNot applicableNCT07766980
Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
RecruitingPhase 2NCT07287189
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 61 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Duchenne Muscular Dystrophy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: TREAT-NMD DMD Global Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is caused by mutations in the DMD gene that prevent production of functional dystrophin, a protein essential for muscle membrane stability. Progressive muscle degeneration leads to loss of ambulation typically by age 12, followed by cardiac and respiratory involvement. Multiple exon-skipping therapies and one gene therapy have received FDA approval. Becker MD is the milder allelic form where some dystrophin is produced.
Common clinical features
Progressive muscle weaknessElevated circulating creatine kinaseSkeletal muscle atrophyCalf muscle hypertrophyWaddling gaitProximal muscle weaknessScoliosisCardiomyopathy
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Duchenne Muscular Dystrophy. Not eligibility rules; those are set by each study.
- Specific DMD mutation (exon deletion, duplication, or point mutation) is essential - many trials target specific exons (e.g., exon 51, 53)
- Ambulatory status (walking vs. non-ambulatory) divides most trial populations
- Corticosteroid use (deflazacort, prednisone, or vamorolone) and history is typically required at baseline
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).